Joint

Why you shouldn’t be afraid to start running after middle age

Retrieved on: 
星期五, 四月 19, 2024
Knee, Atrophy, Pressure, MRI, Osteopenia, Exercise, Walking, Activity, Cell, Bone marrow, Chemical oxygen demand, Risk, Gamer, Research, Sarcopenia, Running, Rest, Joint, Volunteering, Life, Arthritis, Osteoporosis, Spine, Bed rest, Cartilage, Osteoarthritis, Skeleton, Dietary supplement

As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.

Key Points: 
  • As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.
  • Hobbling around my orthopaedic hospital after my first marathon actually led me to do research on runners.
  • The high-resolution MRI scans found most of the 115 middle-aged participants had abnormalities in their knees before starting marathon training.
  • But while osteoarthritis is more common after middle age, it may actually be a lack of activity that leads to osteoarthritis.
  • Reduced muscle use, whether it is through inactivity or sarcopenia or both, also reduces the production of anti-inflammatory myokines from the muscles.
  • These chemicals are released when we exercise, and help reduce joint swelling and calm irritated joint linings.
  • This effect is pronounced in runners because running uses some of the largest muscles in the body – such as the glutes, quadriceps and hamstrings.

Where to begin

  • If you want to start running, the main message is to ease into it to reduce the risk of injury.
  • One of the best ways to ease into running in mid-life is the NHS Couch to 5K running programme.
  • It’s a free guide that will help you gradually work up towards running 5km in just nine weeks.
  • If you’ve experienced any of these problems, you’ll want to be careful when exercising to avoid further damage.


Alister Hart receives funding from 3 charities: The Rosetrees Trust, Arthroplasty for Arthritis and The Maurice Hatter Foundation.

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant Treatment of haemophilia B, 26/10/2018 Withdrawn

Retrieved on: 
星期四, 四月 18, 2024
Eurostat, Diagnosis, Civil service commission, Brain, Disease, Coagulation, Patient, Committee, Knowledge, Internal, Regulation, Haemophilia, EMA, IRIS, Joint, Human, Wound healing, Clinical trial, European, Therapy, COMP, Bleeding, Spinal cord, Sponsor, European Commission, Immune system, Antibody, Safety, Factor IX, Blood, Marketing, Limited, Haemophilia B, Medicine, Pharmaceutical industry

Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant Treatment of haemophilia B, 26/10/2018 Withdrawn

Key Points: 


Orphan designation: Recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant Treatment of haemophilia B, 26/10/2018 Withdrawn

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Retrieved on: 
星期四, 四月 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Anthraquinones, Skin cancer, Epidermolysis bullosa, Disease, Inflammation, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Joint, Protein, Life expectancy, Deformity, Blister, Interleukin-1 family, Mouth, European, Skin, Collagen, COMP, Infection, Safety, European Commission, Pain, Osteoarthritis, Marketing, Swelling, FGK, Medicine, Pharmaceutical industry

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Key Points: 


Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Joint HMA/EMA Big Data Steering Group workshop on RWE methods, Online, European Medicines Agency, Amsterdam, the Netherlands, 14 June 2024

Retrieved on: 
星期四, 四月 18, 2024
RWE, Patient, Joint, Date, EMA, Industrial design

Joint HMA/EMA Big Data Steering Group workshop on RWE methods

Key Points: 
  • Joint HMA/EMA Big Data Steering Group workshop on RWE methods
    EventHumanData on medicines
    Date
    Location
    This one-day hybrid Big Data Steering Group (BDSG) workshop will bring together representatives of regulatory agencies, pharmaceutical companies, patients, healthcare professionals, academia, and health technology assessment bodies to address the following objectives:
    You can register for the workshop at the following link:
    Registration for the Joint HMA/EMA Big Data Steering Group Workshop on RWE methods

EQS-News: Ekosem-Agrar AG plans to restructure its outstanding corporate bonds

Retrieved on: 
星期三, 四月 10, 2024
EUR, SDK, Joint, ESA, Webcast, FAQ, Sale, Bank statement, Federal Gazette, Gesellschaft mit beschränkter Haftung, Security (finance)

The proposed measures essentially comprise the sale and transfer of the outstanding bonds including accrued interest at a purchase price of EUR 300.00 per bond with a nominal value of EUR 1,000.00.

Key Points: 
  • The proposed measures essentially comprise the sale and transfer of the outstanding bonds including accrued interest at a purchase price of EUR 300.00 per bond with a nominal value of EUR 1,000.00.
  • Furthermore, the management plans to merge the German holding company with the operating business, which is based exclusively in Russia.
  • The current shareholders of Ekosem-Agrar AG will essentially hold the shares in the acquiring company.
  • Our bonds have been an important financial pillar in building up our business since 2012, combined with an attractive return for our noteholders.

EQS-News: Telefónica Deutschland's Management Board and Supervisory Board jointly recommend acceptance of the public delisting acquisition offer

Retrieved on: 
星期三, 四月 10, 2024
Offer, EUR, Joint, Supervisory board, Environment, Supervision, Acquisition, Management, S.A, Property management

The Management Board and the Supervisory Board of Telefónica Deutschland Holding AG ("Telefónica Deutschland") today issued their Joint Reasoned Statement on the voluntary public acquisition offer (“Offer”) by Telefónica Local Services GmbH (“Bidder”), of which Telefónica, S.A. is the sole shareholder, for all shares of Telefónica Deutschland not directly held by the Bidder ("Telefónica Deutschland Shares") against a cash consideration of EUR 2.35 per share (“Offer Price”).

Key Points: 
  • The Management Board and the Supervisory Board of Telefónica Deutschland Holding AG ("Telefónica Deutschland") today issued their Joint Reasoned Statement on the voluntary public acquisition offer (“Offer”) by Telefónica Local Services GmbH (“Bidder”), of which Telefónica, S.A. is the sole shareholder, for all shares of Telefónica Deutschland not directly held by the Bidder ("Telefónica Deutschland Shares") against a cash consideration of EUR 2.35 per share (“Offer Price”).
  • After a careful review of the offer document published by the Bidder on 20 March 2024, the Management Board and the Supervisory Board of Telefónica Deutschland consider the Offer to be fair from a financial point of view.
  • The Management Board and the Supervisory Board of Telefónica Deutschland refrained from obtaining additional fairness opinions.
  • The Management Board and – based on the recommendation of its specially established Acquisition Offer Committee, which is composed exclusively of independent members – the Supervisory Board of Telefónica Deutschland support the Bidder’s Offer and recommend the shareholders to accept the Offer.

Li Ning Company Continued to Pursue the Core Strategy of "Single Brand, Multi-Categories, Diversified Channels", Focused on Core Categories to Achieve Stable Development

Retrieved on: 
星期三, 三月 20, 2024
Automation, Li-Ning, POS, Culture, Benchmarking, Joint, Sport, Growth, Motivation, Communication, RMB, Omnichannel, Research, Running, Multi, Investment, Creativity, Safety, HKD, Basketball, Marketing, Football, Hand, Retail

In 2023, the Group continued to focus the core strategy of "Single Brand, Multi-categories, Diversified Channels" with a focus on professional sports in the five core categories, namely basketball, running, fitness, badminton, and sports casual.

Key Points: 
  • In 2023, the Group continued to focus the core strategy of "Single Brand, Multi-categories, Diversified Channels" with a focus on professional sports in the five core categories, namely basketball, running, fitness, badminton, and sports casual.
  • Through its efforts dedicated to brand reputation and product innovation, the Group has developed a comprehensive layout of functional products.
  • In 2023, the Group continued to focus on the core strategy of "Single Brand, Multi-categories, Diversified Channels" and optimized LI-NING's experience value continuously.
  • The Group focused on building the competitive advantages of products from its core categories.

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN INDIANAPOLIS, INDIANA

Retrieved on: 
星期一, 四月 8, 2024
Arthralgia, Osteoarthritis, DVM, Mayra Andrade, Hip, Patient, Synovial joint, Pain management, ACVS, Limp, Quality of life, Trial of the century, Dog, JW Marriott Hotels, JW Marriott Indianapolis, Joint, Pain, CCRT, VOS, Animal, CCD, Poultry farming

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
  • For more information about PetVivo Holdings, Inc. please contact [email protected] or visit https://petvivo.com/
    Pain Management Forum Exhibit Details:
    Location: The JW Marriott in Indianapolis, Indiana
    Presentation Title: How do we Elevate Our Strategy for Managing Osteoarthritis in Pets?

PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE ACVSMR SYMPOSIUM IN NAPLES FLORIDA

Retrieved on: 
星期三, 四月 3, 2024
Arthralgia, Osteoarthritis, American College, Joint, Pet, Animal, Sports medicine

PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.

Key Points: 
  • PetVivo intends to exhibit its lead product, SPRYNG™ with OsteoCushion™ Technology.
  • Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles.
  • The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue.
  • Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.

Bestqool Revolutionizes Outdoor Activities with Innovative Red Light Therapy Devices

Retrieved on: 
星期三, 四月 3, 2024
RLT, Psoriasis, Motivation, Exercise, Chemical oxygen demand, System, Mitochondrion, Motion, Joint, Life, Athlete, Acne, Facial muscles, Skin, Oxygen, Red light, Health, Low-level laser therapy, Medical imaging

Seattle, Washington, April 03, 2024 (GLOBE NEWSWIRE) -- Bestqool has announced its innovative approach to integrating Red Light Therapy (RLT) with outdoor exercises and sports routines.

Key Points: 
  • Seattle, Washington, April 03, 2024 (GLOBE NEWSWIRE) -- Bestqool has announced its innovative approach to integrating Red Light Therapy (RLT) with outdoor exercises and sports routines.
  • Red Light Therapy is an advanced therapy mode that uses low-level wavelengths of red light to focus on the skin or deeper tissues, as needed to help resolve their related issues.
  • [2]
    Because of the invention of several hand-held devices, using Red Light Therapy within the comforts of your home has also been made possible.
  • When it comes to talking about top-notch, great-quality hand-held Red Light Therapy devices, Bestqool is your ultimate solution.